HCC
DDW 2025 Expert Picks, Part 1
In part 1 of the DDW Expert Picks column, we review top abstracts from the ASGE program ...
JULY 24, 2025
More Data on Role of Statins in Prevention of HCC and Chronic Liver Disease
A new large retrospective study lends further credence to the evolving theory that statins may help prevent ...
JUNE 17, 2025
FDA Approves Checkpoint Inhibitor Combination For Unresectable or Metastatic HCC
The FDA has approved nivolumab with ipilimumab for the first-line treatment of adults with unresectable or ...
JUNE 11, 2025
First-Degree Relatives of MASLD Patients Are at Higher Risk for HCC
Some relatives of people with metabolic dysfunction–associated steatotic liver disease are at higher risk for ...
DECEMBER 24, 2023
New Research, Guidelines and More That Changed Gastroenterology in 2023
The gastroenterology field was full of new developments in 2023.
DECEMBER 21, 2023
Albumin-Bilirubin Grade Proposed as Prognostic Tool in Hepatocellular Carcinoma
Results of a retrospective study suggest that the albumin-bilirubin grade might be more useful in classifying ...
OCTOBER 30, 2023
Nonalcoholic Steatohepatitis: Identifying High-Risk Patients
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat deposition in the liver in the absence ...
AUGUST 30, 2022
Survey Uncovers Barriers To HCC Surveillance
In the surveillance of patients with known risk factors for hepatocellular carcinoma, numerous obstacles exist on ...
MAY 22, 2022
High Blood Iron Levels May Increase Risk for HCC in NAFLD
NAFLD patients with high blood iron levels may be at an increased risk for developing HCC.
APRIL 4, 2022
Researchers Question Value of 30-Day Readmission Metric in HCC
Researchers at several centers across the country are raising doubts about rates of 30-day readmission after liver ...
FEBRUARY 7, 2022
Surgeons Propose New Risk Model for 30-Day Mortality After Major Liver Resection
A cluster of eight factors appears to help surgeons predict which patients scheduled for major liver resection are ...
NOVEMBER 8, 2021
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb has voluntarily withdrawn from the U.S. market the indication ...
JULY 30, 2021
